Innealta Capital’s Keros Therapeutics KROS Stock Holding History

Innealta Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22	Closed	-$1K	–	968
2024 Q2	$1K	Buy	+22	New	+$1.18K	﹤0.01%	1318

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Innealta Capital's KROS Position: Q3 2024 in Review

Innealta Capital sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 22 shares — an estimated $1K sold.

Innealta Capital first reported a position in KROS in Q2 2024 and held it in 1 quarter. The position peaked at $1K in Q2 2024. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

Innealta Capital reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 22 Keros Therapeutics shares in Q3 2024, an estimated $1K.
Innealta Capital first reported a position in Keros Therapeutics in Q2 2024 and held it in 1 quarter.
Innealta Capital's Keros Therapeutics position peaked at $1K in Q2 2024.
163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.